funded by the China Crohn’s&Colitis Foundation[grant number CCCF-QF-2022A53-2].
Background:The efficacy of anti-TNF therapy in Crohn’s disease(CD),such as infliximab,is often compromised by the development of anti-drug antibodies(ADAs).The genetic variation HLA-DQA1*05 has been linked to the imm...